IMUNA PHARM

Executive Summary

IMUNA PHARM, founded in 1991 and headquartered in Bratislava, Slovakia, is a pharmaceutical company operating in the oncology and immunology sectors. The company develops immunotherapies and cancer treatments leveraging advanced immunological approaches. Additionally, IMUNA PHARM maintains a commercial business manufacturing disinfectants and other pharmaceutical products under GMP standards, providing a steady revenue stream. Despite its long history, the company remains privately held with limited public information regarding its pipeline, funding, or valuation, and has minimal online engagement or profile completeness. This suggests a conservative, low-profile operational strategy focused on regional markets. The dual focus on commercial products and R&D may offer financial stability but also poses challenges in scaling innovative therapies without external investment or partnerships. Overall, IMUNA PHARM represents a small, established European biopharma player with potential in immunotherapy, though its impact and visibility are currently constrained.

Upcoming Catalysts (preview)

• TBDLaunch of new disinfectant or pharmaceutical product60% success
• TBDPartnership or licensing deal for immunotherapy platform20% success
• TBDPublication of preclinical or clinical data for cancer treatment15% success